Joel Greenblatt’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.07M | Sell |
100,271
-129,556
| -56% | -$10.9M | 0.02% | 818 |
|
|
2026
Q1 | $18.4M | Buy |
229,827
+107,374
| +88% | +$8.85M | 0.06% | 487 |
|
|
2025
Q4 | $10.4M | Buy |
122,453
+88,997
| +266% | +$7.3M | 0.04% | 623 |
|
|
2025
Q3 | $2.6M | Sell |
33,456
-9,839
| -23% | -$769K | 0.01% | 934 |
|
|
2025
Q2 | $3.39M | Sell |
43,295
-365
| -0.8% | -$27.2K | 0.02% | 767 |
|
|
2025
Q1 | $3.16M | Buy |
43,660
+27,237
| +166% | +$1.95M | 0.03% | 655 |
|
|
2024
Q4 | $1.22M | Buy |
16,423
+8,444
| +106% | +$591K | 0.01% | 859 |
|
|
2024
Q3 | $527K | Sell |
7,979
-3,879
| -33% | -$282K | 0.01% | 1091 |
|
|
2024
Q2 | $1.1M | Buy |
11,858
+30
| +0.3% | +$2.66K | 0.01% | 864 |
|
|
2024
Q1 | $1.13M | Sell |
11,828
-6,468
| -35% | -$543K | 0.02% | 810 |
|
|
2023
Q4 | $1.4M | Buy |
18,296
+6,738
| +58% | +$469K | 0.03% | 699 |
|
|
2023
Q3 | $801K | Sell |
11,558
-10,835
| -48% | -$871K | 0.02% | 844 |
|
|
2023
Q2 | $2.11M | Sell |
22,393
-24,129
| -52% | -$2.1M | 0.05% | 527 |
|
|
2023
Q1 | $3.85M | Sell |
46,522
-4,731
| -9% | -$372K | 0.09% | 280 |
|
|
2022
Q4 | $3.82M | Buy |
51,253
+24,513
| +92% | +$1.89M | 0.11% | 235 |
|
|
2022
Q3 | $2.21M | Buy |
26,740
+20,684
| +342% | +$1.99M | 0.07% | 364 |
|
|
2022
Q2 | $576K | Sell |
6,056
-12,995
| -68% | -$1.35M | 0.02% | 746 |
|
|
2022
Q1 | $2.24M | Buy |
19,051
+13,398
| +237% | +$1.5M | 0.07% | 329 |
|
|
2021
Q4 | $732K | Sell |
5,653
-4,593
| -45% | -$536K | 0.02% | 633 |
|
|
2021
Q3 | $1.16M | Buy |
+10,246
| New | +$1.17M | 0.05% | 447 |
|
|
2020
Q3 | – | Sell |
-16,482
| Closed | -$1.14M | – | 1061 |
|
|
2020
Q2 | $1.14M | Buy |
+16,482
| New | +$1.17M | 0.03% | 533 |
|
|
2020
Q1 | – | Sell |
-89,811
| Closed | -$6.98M | – | 1106 |
|
|
2019
Q4 | $6.98M | Buy |
+89,811
| New | +$7.01M | 0.13% | 225 |
|
|
2018
Q1 | – | Sell |
-112,623
| Closed | -$4.23M | – | 981 |
|
|
2017
Q4 | $4.23M | Buy |
112,623
+88,815
| +373% | +$3.26M | 0.06% | 379 |
|
|
2017
Q3 | $867K | Buy |
+23,808
| New | +$908K | 0.01% | 621 |
|
|
2016
Q3 | – | Sell |
-17,511
| Closed | -$582K | – | 953 |
|
|
2016
Q2 | $582K | Buy |
+17,511
| New | +$599K | 0.01% | 705 |
|
|
2015
Q4 | – | Sell |
-46,662
| Closed | -$1.11M | – | 899 |
|
|
2015
Q3 | $1.11M | Sell |
46,662
-618,822
| -93% | -$14.9M | 0.01% | 608 |
|
|
2015
Q2 | $15.8M | Sell |
665,484
-783,318
| -54% | -$17.7M | 0.13% | 240 |
|
|
2015
Q1 | $34.4M | Sell |
1,448,802
-38,454
| -3% | -$863K | 0.26% | 140 |
|
|
2014
Q4 | $31.6M | Sell |
1,487,256
-150,708
| -9% | -$3.03M | 0.26% | 145 |
|
|
2014
Q3 | $27.9M | Buy |
1,637,964
+83,526
| +5% | +$1.32M | 0.28% | 131 |
|
|
2014
Q2 | $22.2M | Buy |
1,554,438
+1,124,304
| +261% | +$15.2M | 0.28% | 119 |
|
|
2014
Q1 | $5.32M | Sell |
430,134
-276,426
| -39% | -$3.19M | 0.08% | 354 |
|
|
2013
Q4 | $7.74M | Buy |
706,560
+520,014
| +279% | +$5.86M | 0.18% | 181 |
|
|
2013
Q3 | $2.17M | Sell |
186,546
-66,186
| -26% | -$774K | 0.07% | 409 |
|
|
2013
Q2 | $2.83M | Buy |
+252,732
| New | +$2.99M | 0.12% | 250 |
|
Other funds holding EW
Joel Greenblatt's EW Position: Q2 2026 in Review
Joel Greenblatt reduced its Edwards Lifesciences (EW) stake by 56% in Q2 2026, selling an estimated $10.9M and leaving 100,271 shares worth $9.07M. The position accounts for 0.02% of the portfolio, ranked #818.
Joel Greenblatt first reported a position in EW in Q2 2013 and has held it in 35 quarters since. The position peaked at $34.4M in Q1 2015. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Joel Greenblatt held 100,271 shares of Edwards Lifesciences worth $9.07M as of Q2 2026.
- Joel Greenblatt sold 129,556 Edwards Lifesciences shares in Q2 2026, an estimated $10.9M.
- Edwards Lifesciences made up 0.02% of Joel Greenblatt's portfolio in Q2 2026, its #818 holding.
- Joel Greenblatt first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 35 quarters since.
- Joel Greenblatt's Edwards Lifesciences position peaked at $34.4M in Q1 2015.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.